Compositions and methods of use of an oncolytic vesicular stomatitis virus
Oncolytic VSV viruses have been developed as a strategy for combating cancer. The present invention includes mutant VSV that have one or more mutations in the nucleic acid sequence encoding the viral genome that increase the oncolytic potential of the virus. Pharmaceutical compositions including oncolytic virus disclosed herein are also provided. Pharmaceutical compositions containing virus and one or more excipients may be for systemic or local administration. Methods of administering an effective amount of the compositions for treating cancer are disclosed. Preferred routes of administration include intratumeral and intravenous injection, and intranasal delivery. Administration of the disclosed compositions containing oncolytic viruses may be coupled with surgical, radiologic, other therapeutic approaches to treatment of cancer. Methods of manufacturing mutant VSV viruses exhibiting desired properties include applying selective pressure, and through directed or random mutagenesis.
1. An isolated oncolytic VSV virus comprising one or more changes in nucleic acid sequence resulting in substitution of the serine at codon 126 of SEQ ID NO. 3, with an amino acid selected from the group consisting of alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glutamine (Q), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), tryptophan (W), or valine (V) and substitution of aspartic acid (D) at codon 223 of SEQ ID NO. 5 with an amino acid selected from the group consisting of serine (S), threonine (T), or tyrosine (Y).
2. The isolated oncolytic VSV virus of claim 1 , wherein the serine (S) at codon 126 SEQ ID NO. 3, is substituted with leucine (L) and the aspartic acid (D) at codon 223 of SEQ ID NO. 5 is substituted with a tyrosine (Y).
3. An isolated oncolytic VSV virus with SEQ ID NO: 6.
4. The isolated oncolytic VSV virus of claim 1 , wherein the virus is engineered to express one or more additional genes encoding proteins selected from the group consisting of targeting proteins and therapeutic proteins.
5. A sterile pharmaceutical dosage unit composition comprising an effective amount of the oncolytic virus of claim 1 to reduce tumor burden.
6. The dosage unit of claim 5 , in an amount of virus effective to systemically treat an individual having metastastic cancer.
7. The dosage unit of claim 5 , comprising an amount of virus effective to locally or regionally treat a tumor.
8. A method for treating cancer comprising administering to a subject in need thereof an effective mount of the viral dosage unit of claim 5 .
9. The method of claim 8 , wherein the cancer is selected from the group consisting of bone, bladder, brain, breast, cervical, colo-rectal, esophageal, kidney, liver, lung, nasopharangeal, pancreatic, prostate, skin, stomach, and uterine.
10. The method of claim 8 , wherein the cancer is a vascular cancer such as multiple myeloma, an adenocarcinomas or a sarcoma.
11. The method of claim 9 , comprising administering a viral dosage unit effective to treat a glioma.
12. The method of claim 8 , wherein the viral dosage unit is administered intratumorally or parenterally.
13. The method of claim 8 , wherein the viral dosage unit is administered in combination with a second therapeutic agent selected from the group consisting of immunosuppressants, anticancer agents, and therapeutic proteins.